Nasal administration of insulin is successfully used as a treatment for Alzheimer’s disease, and type-2 diabetes is associated with the risk of developing Alzheimer’s disease (Reger et al., 2008; Craft et al., 2012; Akinola, 2016). Here, INS is linked to early-onset autosomal dominant Alzheimer disease.